Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study

The primary objective of this study is o evaluate whether early treatment with venetoclax and obinutuzumab (V-O) extends overall survival (OS) compared with delayed treatment with V-O in highrisk (chronic lymphocytic leukemia [CLL] international prognostic indicator [CLLIPI] ≥4 or complex cytogenetics), newly diagnosed asymptomatic CLL/SLL patients